These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 3127585)

  • 61. International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review.
    Rosery H; Bergemann R; Maxion-Bergemann S
    Pharmacoeconomics; 2005; 23(3):243-57. PubMed ID: 15836006
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Review of health economics modelling in rheumatoid arthritis.
    Emery P
    Pharmacoeconomics; 2004; 22(2 Suppl 1):55-69. PubMed ID: 15157004
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A clinical and economic review of disease-modifying antirheumatic drugs.
    Gabriel SE; Coyle D; Moreland LW
    Pharmacoeconomics; 2001; 19(7):715-28. PubMed ID: 11548909
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Auranofin versus placebo in rheumatoid arthritis.
    Suarez-Almazor ME; Spooner CH; Belseck E; Shea B
    Cochrane Database Syst Rev; 2000; 2000(2):CD002048. PubMed ID: 10796461
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II.
    Samsa G; Edelman D; Rothman ML; Williams GR; Lipscomb J; Matchar D
    Pharmacoeconomics; 1999 Feb; 15(2):141-55. PubMed ID: 10351188
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Statistical analysis in pharmacoeconomic studies. A review of current issues and standards.
    Coyle D
    Pharmacoeconomics; 1996 Jun; 9(6):506-16. PubMed ID: 10160478
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The costs of rheumatoid arthritis.
    Allaire SH; Prashker MJ; Meenan RF
    Pharmacoeconomics; 1994 Dec; 6(6):513-22. PubMed ID: 10155281
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Statistical versus quantitative significance in the socioeconomic evaluation of medicines.
    O'Brien BJ; Drummond MF
    Pharmacoeconomics; 1994 May; 5(5):389-98. PubMed ID: 10147230
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Randomized trial of switching rheumatoid arthritis patients in remission with injectable gold to auranofin.
    Prete PE; Zane J; Krailo M; Bulanowski M
    Clin Rheumatol; 1994 Mar; 13(1):60-9. PubMed ID: 8187446
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Rational use of disease-modifying antirheumatic drugs.
    Furst DE
    Drugs; 1990 Jan; 39(1):19-37. PubMed ID: 2178910
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Economic evaluation of gastric ulcer prophylaxis in patients with arthritis receiving non-steroidal anti-inflammatory drugs.
    Knill-Jones R; Drummond M; Kohli H; Davies L
    Postgrad Med J; 1990 Aug; 66(778):639-46. PubMed ID: 2120690
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Measuring performance in clinical rheumatology.
    Scott DL; Haslock I
    Ann Rheum Dis; 1990 Jan; 49(1):3-5. PubMed ID: 2106840
    [No Abstract]   [Full Text] [Related]  

  • 73. Intra-articular steroids: confounder of clinical trials.
    Taylor HG; Fowler PD; David MJ; Dawes PT
    Clin Rheumatol; 1991 Mar; 10(1):38-42. PubMed ID: 2065506
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Performance appraisal of internal health services].
    Boutat A; Eggli Y; Frutiger P
    Soz Praventivmed; 1992; 37(4):179-87. PubMed ID: 1414019
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The cost effectiveness of auranofin: results of a randomized clinical trial.
    Thompson MS; Read JL; Hutchings HC; Paterson M; Harris ED
    J Rheumatol; 1988 Jan; 15(1):35-42. PubMed ID: 3127585
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Dose response studies and longterm evaluation of auranofin in rheumatoid arthritis.
    Champion GD; Cairns DR; Bieri D; Adena MA; Browne CD; Cohen ML; Day RO; Edmonds JP; Graham GG; de Jager J
    J Rheumatol; 1988 Jan; 15(1):28-34. PubMed ID: 3280795
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Hematuria in patients with rheumatoid arthritis receiving gold and D-penicillamine.
    Leonard PA; Bienz SR; Clegg DO; Ward JR
    J Rheumatol; 1987 Feb; 14(1):55-9. PubMed ID: 3106632
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Auranofin improves outcome in early rheumatoid arthritis. Results from a 2-year, double blind placebo controlled study.
    Borg G; Allander E; Lund B; Berg E; Brodin U; Pettersson H; Trang L
    J Rheumatol; 1988 Dec; 15(12):1747-54. PubMed ID: 14552308
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Auranofin in the treatment of rheumatoid arthritis: a multicenter double-blind prospective clinical trial].
    Yang JL
    Zhonghua Nei Ke Za Zhi; 1993 Jul; 32(7):486-8. PubMed ID: 8275829
    [No Abstract]   [Full Text] [Related]  

  • 80. Measuring costs and financial benefits in randomized controlled trials.
    Bulpitt CJ; Fletcher AE
    Am Heart J; 1990 Mar; 119(3 Pt 2):766-70; discussion 770-1. PubMed ID: 2106770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.